U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908550) titled 'Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer' on Oct. 26.
Brief Summary: The trial will assess the efficacy, safety, and tolerability of daraxonrasib monotherapy in Asian patients with RAS-mutated advanced biliary tract cancer in second-line treatment. The Primary Endpoint is Objective Response Rate (ORR).
Study Start Date: Jan., 2027
Study Type: INTERVENTIONAL
Condition:
Biliary Tract Cancer (BTC)
Intervention:
DRUG: Daraxonrasib
Daraxonrasib 300 mg orally once daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: National Health Research Institutes, Taiwan
Disclaimer: Curated by HT Syndication....